Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crenolanib - AROG Pharmaceuticals/Pfizer

Next Previous
Drug Profile

Crenolanib - AROG Pharmaceuticals/Pfizer

Alternative Names: ARO-002; ARO-002-26; CP-868,596; CP-868,596-26; Crenolanib besylate - AROG Pharmaceuticals/Pfizer; IND-112201

Latest Information Update: 27 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AROG Pharmaceuticals
  • Class Amines; Antineoplastics; Benzimidazoles; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Acute myeloid leukaemia; Soft tissue sarcoma; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Gastrointestinal stromal tumours
  • Phase II Glioblastoma
  • No development reported Gastric cancer; Glioma; Oesophageal cancer
  • Discontinued Non-small cell lung cancer; Soft tissue sarcoma; Systemic mastocytosis

Most Recent Events

  • 03 Apr 2026 Arog Pharmaceuticals completes a phase III trial in Acute myeloid leukaemia (Second-line therapy or greater) in the US, Canada, France, Germany, Italy and Spain (PO) (NCT03250338)
  • 06 Dec 2025 Efficacy and adverse events data from a phase III trial in Acute myeloid leukemia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH 2025)
  • 07 Dec 2024 Adverse events and efficacy data from the phase II trial in Acute myeloid leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top